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Abstract 
Purpose: To investigate the inhibitory effect of rhubarb on α-glucosidase activity in the small intestine of 
rats with type 1 diabetes.  
Methods: Type 1 diabetic rat model was established by intraperitoneally injecting 30 male SD rats with 
1 % streptozocin (STZ). Rats with fasting blood glucose > 11 mmol/L (24) were used for the study. The 
rats were randomly divided into three equal groups including control, acarbose and rhubarb groups. 
Arcabose® (20 mg/kg /day) and rhubarb (100 mg/kg /day) were given by intra-gastric route via insertion 
of the cannula through the esophagus. Daily fasting blood glucose and daily postprandial glucose levels 
were assayed for all groups. On day 6, postprandial blood glucose, blood levels of C-peptide and 
insulin, and intestinal α-glucosidase were also determined.  
Results: There were no significant differences in levels of C-peptide, insulin and fasting blood glucose 
between control, Acarbose® and rhubarb groups (p > 0.05). However, α-glucosidase activity at 0, 30, 60 
and 120 min in the rhubarb group was 1759.2, 1812.8, 1379.8 and 772.1 U, respectively,) while in the 
Acarbose® group it was 178.6, 1260.1, 1126.5, 599.2 U, respectively. α-Glucosidase activity in both 
groups initially showed an increase (p < 0.05), followed by a decline from 60 to 120 min (p ˂ 0.05). After 
120 min, α-glucosidase activity in each of the two groups was significantly decreased compared with 
untreated control (1200 U) (p ˂ 0.05).  
Conclusion: The inhibitory effect of rhubarb on intestinal α-glucosidase activity of Type 1 diabetic rats 
is comparable to that of Arcabose®.This suggests that this plant may have clinically potent anti-diabetic 
properties. 
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As a serious and chronic metabolic disorder, 
diabetes mellitus can be reflected by the 
increased levels of hemoglobin, fasting blood 
glucose and postprandial blood glucose [1]. 
Diabetic patients manifest impaired glucose 
tolerance which is a consequence defects in the 
function or secretion of insulin. Impaired glucose 
tolerance results in postprandial hyperglycemia 
[2]. The α-glucosidase inhibitors (Miglitol®, 
Voglibose® and Acarbose®) are used for 
improving insulin sensitivity and decreasing 
postprandial hyperglycemia, through suppressing 
intestinal absorption of carbohydrates [3]. Type 1 
diabetes, which is caused by insulin deficiency 
can be treated with α-glucosidase inhibitors [4]. 
Acarbose® is a popular α-glucosidase inhibitor 
[5]. α-Glucosidase activity has unique 
advantages in the treatment of diabetes mellitus, 
especially in reducing postprandial blood 
glucose. Acarbose® treatment, which is 
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recommended by Asia Pacific Diabetes Drug 
Guide, is the first-line therapy of postprandial 
blood glucose reduction [6]. 
 
However, the use of Acarbose® is associated 
with problems of intolerance. In some patients, it 
produces intestinal problems, one of which is 
flatulence [7]. Therefore, the development of 
novel drugs with high activity and low 
mammalian toxicity is urgently needed. In this 
regard, the high and efficacy of herbs-derived 
drugs have attracted more and more attentions 
[8]. With the antibacterial, anti-tumor, anti-
mutagenic and purgative activities, dried rhubarb 
rhizome was widely used in the traditional 
Chinese medicine. The main bioactive 
constituents of rhubarb are anthraquinone 
derivatives, which can induce apoptosis, inhibit 
cellular proliferation and prevent metastasis [9]. 
However, the anti-diabetic properties of rhubarb 
have not been well studied [10].  
 
This study was carried out to investigate the 
effects of rhubarb on intestinal α-glucosidase and 
other indices (postprandial blood glucose, C-
peptide protein, insulin and fasting blood 






Rhubarb (fine powder, Batch no. 110757200206; 
Xiankangwei Biological Engineering Co., Ltd. 
China) was preserved at room temperature. 
Acarbose (H19990205) was a product of Bayer 
Healthcare Pharmaceutical Company, Beijing. 
Alpha-glucosidase activity reagent (MAK123) 
was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Streptozoticin (STZ, 1 %) was 
prepared in 0.1mol/L citric acid buffer, pH 4.3, 
was and preserved at 4 oC.  
 
Animal model  
 
Thirty healthy male SD rats (mean weight = 
171.2 ± 8.6 g) were provided by Guangdong 
Medical Experimental Animal Center (China). 
The rats were kept in SPF animal house in 
Guangdong Medical Experimental Animal Center 
(license number: SYXK (Guangdong 2013-0002). 
They were housed in numbered cages in a room 
with a 10h light/14h dark cycle at 23 ± 3 °C and 
moisture level of 55 ± 15 %. Pellet feed 
containing 33.9 % starch, and water were 
provided ad libitum. The rats were fasted 
overnight (12 h) and given intraperitoneal 
injection of 1 % STZ solution (6 mL/kg body 
weight). After 7 days, the fasting blood glucose of 
the rats was measured after 5h fast. Rats with 
fasting blood- glucose ≥ 11.0 mmol / L were 
chosen as experimental models. This research 
was approved by the Animal Ethics Committee of 
Guangdong Provincial experimental Animal 
Center (approval ref no. B201504-9).  All the 
animal experiments were performed according to 
“Guidelines for Ethical Conduct in the Care and 




Twenty-four model rats were randomly divided 
into control group (given saline), Acarbose group, 
and rhubarb group. Each group had 8 rats. In the 
acarbose group, rats were subjected to intra-
gastric administration of 20 mg AcarboseR /kg 
body weight/day. Rats in the rhubarb group 
received 100 mg rhubab/kg body weight/day, 
also via the intra-gastric route through insertion 
of the cannula via the esophagus, the dose were 
determined according the previous studies 
[12,13]. In both groups, the dose selection was 
based on estimated intake for a 60 kg reference 
man. In the control group, rats received intra-
gastric saline once a day. Treatments for all 
groups were given at the same time. Rats in all 
groups were monitored physical changes and 
general performance. Each rat was weighed 
every two days, and the weight was recorded. 
Pelleted feed and clean drinking water were 
provided ad libitum throughout the period of 
study (7 days).From day one to day six, fasting 
blood-glucose determined daily after 4h fast, 
after which feeding was restored. Then 
postprandial glucose was assayed. Water supply 
was not disrupted at any stage of the study. On 
the 7th day, fasting and postprandial (30 min, 60 
min and 120 min) blood glucose, as well as C 
peptide insulin and intestinal α-glucosidase 
activities were determined.  
 
Assay of α-glucosidase activity 
 
The rats were sacrificed under anaethesia, and 
the intestinal contents were cleared. The mucous 
membrane lining of the small intestine was 
carefully scraped onto an ice plate, and added to 
phosphate buffer, pH 6.8 in a volume ratio of 5:1 
(buffer : mucous membrane lining) at 4 oC. The 
mixture was centrifuged (5000 rpm) at 4 oC for 
20min, and the supernatant was preserved at -20 
oC prior to use in the assay of α-glucosidase 
activity. The enzyme was assayed with Sigma-
Aldrich kits (Art. No. MAK123) according to 
manufacturer’s instructions. 
 
Assay of C-peptide and insulin 
 
Serum C peptide and insulin were determined by 
enzyme-linked immunosorbate assay (ELISA). 
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Statistical significance was evaluated by one-way 
ANOVA using SPSS 21 (SPSS Institute, Cary, 





There were no significant differences in fasting 
blood glucose, C-peptide and insulin between 
groups (p > 0.05) (Figure 1, Figure 2 and Figure 
3). In addition, no significant difference was 
found in postprandial glucose levels between the 
groups at 120 min after feeding from days 1 to 7 
(p > 0.05, Figure 3B). 
 
 
Figure 1: Insulin levels of the three groups. Key:  




Figure 2: C-Peptide levels in the three groups. Key: 
 Control,  Acarbose,  Rhubarb 
 
In addition, there were no significant differences 
in postprandial glucose 120 min after feeding 
from day 1 to day 6 (p > 0.05) (Figure 3B). 
However, intestinal α--glucosidase activity results 
at 0, 30, 60 and 120 min in the rhubarb group 
(1759.2, 1812.8, 1379.8 and 772.1 U, 
respectively) and acarbose (1759.2, 1260.1, 
1126.5 and 599.2 U, respectively) groups 
showed initial increase from time zero to 30 min, 
followed by significant decline from 60 min to 120 
min (p ˂ 0.05). After 120 min, α-glucosidase 
activity in each of the two groups was 
significantly lower than control value (1200 U) (p 
˂ 0.05). 
 
Figure 4: Intestinal α-glucosidase activities in the 





Figure 3: A = Comparison of daily fasting blood 
glucose levels among the three groups ; B = 
Comparison of postprandial blood glucose levels of 
the four groups 120 minutes after meals from Day 1 to 




Prior to the administration of rhubarb and 
Arcabose,  fasting blood glucose levels of rats in  
three groups were all ≥ 11.0mmol/L, and their 
insulin or C-peptide levels were not related to 
feeding. Most of the rats had damaged islet cells 
and hypoinsulinism. These data indicate that 
type 1 diabetes model was successfully 
established in the rats.  
 
Treatment with rhubarb and Acarbose brought 
about significant reduction in the activity of 
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postprandial intestinal α-glucosidase. It is 
interesting to note that there was no significant 
difference in α-glucosidase activity between the 
rhubarb and Acarbose groups. This implies that 
rhubarb has the same level of efficacy as 
Acarbose. Thus rhubarb could be developed into 
a new type of hypoglycemic agent with similar α-
glucosidase inhibitory activity. This will have the 
advantage of overcoming the gastrointestinal 
discomfort usually associated with use of 
AcarboseR [4].  
 
The inhibitory effect of rhubarb may be due to 
anthroquiones, which are its major 
phytochemical components. Strangely, the 
activity of α-glucosidase of rats in these two 
groups was abnormally higher than those of rats 
in the control group. Further studies are needed 
to verify whether this phenomenon was due to 
rebound effect or not. 
 
Pipataline, sesamin, and pellitorine, which inhibit 
the activity ofα-glucosidase, have been applied in 
the prevention and treatment of diabetes [15]. 
Many plants in traditional Chinese medicine can 
significantly inhibit α-glucosidase. MCQ et al 
have carried out a prospective study on the 
treatment of type 2 diabetes with natural 
chemical compounds extracted from plants 
instead synthetic α-glucosidase activity inhibitors 
[16]. Studies have shown that the 
anthroquinones in rhubarb inhibit α-glucosidase 
activity in competitively [16,17]. The results 
obtained in this study further confirm that rhubarb 
possesses α-glucosidase inhibitory activity.  
 
Some studies have shown that the changes in 
the composition of intestinal microflora may be 
the primary cause of α-glucosidase activity 
inhibition. For example, Streptomyces bacteria 
[18] and fermented black bean [19] have been 
reported as inhibitors of α-glucosidase activity. 
Thus it is not unlikely that the inhibition brought 
about by rhubarb might be linked, partially at 





The inhibitory effect of rhubarb extract on 
intestinal α-glucosidase, which was comparable 
to that of acarbose, confirms the anti-diabetic 
potential of rhubarb. This finding is significant in 
the light of efforts to find replacement drugs with 
similar efficacy but less toxicity than Acarbose in 
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